Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: NORTH AMERICAN VACCINE (NVX)

No earlier versions found for this Subject.

Return to NORTH AMERICAN VACCINE (NVX)

MORE NEWS:
" North American Vaccine today announced that the US Patent Office has issued a patent covering chemically modified meningococcal B polysaccharides, and conjugate vaccines incorporating the modified polysaccharides."

Saron Mates, Ph.D, President of North American Vaccine said " This patent significantly enhances the value of the Company's technology and will play a key role in the commercialization of this important vaccine."

This is the sort of news that is driving the stock right now IMO.
NVX is now beginning to be recognized by the investment community as alot more than a one product(DTaP) company. It is my opinion that NVX's pipeline of some 15 different products has alot more value than NVX's present market cap. :-}

Visit their home page and click products. nava.com